Language:

CpG DNA as a vaccine adjuvant

Expert review of vaccines, 2011-04, Vol.10 (4), p.499-511 [Peer Reviewed Journal]

Expert Reviews Ltd 2011 ;COPYRIGHT 2011 Expert Reviews Ltd. ;ISSN: 1476-0584 ;EISSN: 1744-8395 ;DOI: 10.1586/erv.10.174 ;PMID: 21506647

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
CpG DNA as a vaccine adjuvant
Author: Bode, Christian ; Zhao, Gan ; Steinhagen, Folkert ; Kinjo, Takeshi ; Klinman, Dennis M
Subjects: adjuvant ; Adjuvants, Immunologic - administration & dosage ; Adjuvants, Immunologic - adverse effects ; Adjuvants, Immunologic - pharmacology ; Cancer ; Clinical Trials as Topic ; Communicable Disease Control ; Contamination ; CpG oligodeoxynucleotide ; Cytokines ; Dendritic cells ; DNA ; Drug therapy, Combination ; Humans ; Immune response ; immunity ; Immunotherapy ; infectious disease ; Neoplasms - prevention & control ; Neoplasms - therapy ; Oligodeoxynucleotides ; Oligodeoxyribonucleotides - administration & dosage ; Oligodeoxyribonucleotides - adverse effects ; Oligodeoxyribonucleotides - pharmacology ; Oncology, Experimental ; Toll-like receptor ; Tumors ; vaccine ; Vaccines ; Vaccines - immunology
Is Part Of: Expert review of vaccines, 2011-04, Vol.10 (4), p.499-511
Description: Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs trigger cells that express Toll-like receptor 9 (including human plasmacytoid dendritic cells and B cells) to mount an innate immune response characterized by the production of Th1 and proinflammatory cytokines. When used as vaccine adjuvants, CpG ODNs improve the function of professional antigen-presenting cells and boost the generation of humoral and cellular vaccine-specific immune responses. These effects are optimized by maintaining ODNs and vaccine in close proximity. The adjuvant properties of CpG ODNs are observed when administered either systemically or mucosally, and persist in immunocompromised hosts. Preclinical studies indicate that CpG ODNs improve the activity of vaccines targeting infectious diseases and cancer. Clinical trials demonstrate that CpG ODNs have a good safety profile and increase the immunogenicity of coadministered vaccines.
Publisher: England: Informa Healthcare
Language: English
Identifier: ISSN: 1476-0584
EISSN: 1744-8395
DOI: 10.1586/erv.10.174
PMID: 21506647
Source: MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

CpG DNA as a vaccine adjuvant

Expert Reviews Ltd 2011 ;COPYRIGHT 2011 Expert Reviews Ltd. ;ISSN: 1476-0584 ;EISSN: 1744-8395 ;DOI: 10.1586/erv.10.174 ;PMID: 21506647

Searching Remote Databases, Please Wait